PRX, ALKS, Initiated At Buy

September 30, 2010 10:23 AM | 10 seconds read | Make a Comment

UBS has initiated coverage for the following companies: Par Pharmaceutical Companies

PRX

Buy, $35 price target Alkermes Inc.

ALKS

Buy, $18 price target

Posted In: Initiation Analyst Ratings alkermes Biotechnology Health Care par pharmaceutical Pharmaceuticals UBS

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.